問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Cheng Hsin General Hospital (在職)

Division of Cardiovascular Diseases

更新時間：2023-09-19

殷偉賢
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

4Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

殷偉賢

List

19Cases

2009-01-01 - 2013-12-31

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With Acute Coronary Syndrome: Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA•CER)

  • Condition/Disease

    Acute Coronary Symdrome

  • Test Drug

    SCH530348

Participate Sites
13Sites

Terminated13Sites

2012-05-15 - 2014-04-14

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2023-03-01 - 2027-02-28

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
17Sites

Recruiting17Sites

2009-04-16 - 2013-01-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2009-10-31 - 2013-08-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated12Sites

2009-01-20 - 2010-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2018-08-24 - 2021-01-29

Phase II

A randomized parallel-group, placebo-controlled, double-blind, multi-center trial to eValuate the effIcacy and safeTy of the orAL sGC stImulator vericiguaT to improve physical functioning in activities of daily living in patients with heart failure and preserved ejection fraction (VITALITY-HFpEF)

  • Condition/Disease

    正常收縮分率心臟衰竭(HFpEF)

  • Test Drug

    Vericiguat, BAY 1021189

Participate Sites
4Sites

Terminated4Sites

江晨恩
Taipei Veterans General Hospital

Division of Cardiovascular Diseases

2011-09-01 - 2018-12-31

Phase III

A multicentre, international, randomised, parallel group, double blind study to evaluate Cardiovascular safety of linagliptin versus glimepiride in patients with type 2 diabetes mellitus at high cardiovascular risk.

  • Condition/Disease

    type 2 diabetes

  • Test Drug

    Linagliptin

Participate Sites
16Sites

Terminated16Sites

2020-08-01 - 2021-08-19

Phase III

A Phase III, Prospective, Multi-center, Double-blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of Pitavastatin 2 mg/ Ezetimibe 10 mg with Pitavastatin and Ezetimibe in Patients with Primary Hypercholesterolemia or Mixed Dyslipidemia

  • Condition/Disease

    Primary Hypercholesterolemia/Mixed Dyslipidemias

  • Test Drug

    1PC111

Participate Sites
23Sites

Not yet recruiting4Sites

Recruiting19Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB